Cardiac Device Therapy for Heart Failure: An individualized approach
Overview
In this webinar, international experts review the latest evidence in cardiac resynchronization therapy in light of contemporary heart failure medications and the latest analyses on their combination with implantable cardiac defibrillators.
Specifically, the panel discuss the recent HFA, EHRA and EACVI position paper on the optimized Implementation of CRT and its recommended actions:
- Overcoming the underutilization of CRT therapy
- Evaluating and understanding better the pre-implant characteristics
- Critically evaluating terms such as ‘non‐response’ together with the concept of disease modification
- Implementation of a dedicated care pathway for CRT patients post-implant
Key References
1. Mullens W et al. Optimized Implementation of cardiac resynchronization therapy – a call for action for referral and optimization of care A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail 2020, advance access published November 2, 2020
2. Rohde LE et al. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. A PARADIGM-HF Analysis. JACC Heart Fail. 2020 Oct;8(10):844-855
Learning Objectives
- Underlying behaviors leading to substantial underutilization of CRT therapy (with and without a combined implantable cardioverter defibrillator), how these can be addressed/overcome.
- How contemporary pharmaceutical regimens may be impacting timely CRT referral to the detriment of therapeutic synergies and optimal patient outcomes.
- Analyses and research on the various pre-implant characteristics that can impact the decision to implant CRT therapy and the exact device selection (CRT-D vs CRT-P).
- Historical background and evolution of the term “response” and “non-response” to CRT therapy and why these terms may have been used outside of their appropriate context in a therapy area that is by its nature progressive.
- Level of care that needs to be provided after a CRT device is implanted and practical ways of implementing such pathways across international care settings.
Audience
- Cardiologists and electrophysiologists involved in the implantation and follow-up of cardiac implantable devices for heart failure, such as implantable cardioverter defibrillators (ICDs) and Cardiac Resynchronization Therapy device (CRT)
Agenda
